Back to Search
Start Over
Cefoperazone/sulbactam-induced hemolytic anemia
- Source :
- Journal of Postgraduate Medicine.
- Publication Year :
- 2022
- Publisher :
- Medknow, 2022.
-
Abstract
- Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment.
- Subjects :
- Hemolytic anemia
medicine.medical_specialty
medicine.diagnostic_test
business.industry
medicine.drug_class
Abdominal Infection
Cephalosporin
General Medicine
Sulbactam
biochemical phenomena, metabolism, and nutrition
Hematocrit
bacterial infections and mycoses
medicine.disease
Meropenem
Gastroenterology
Cefoperazone
Pharmacotherapy
Internal medicine
polycyclic compounds
medicine
bacteria
business
medicine.drug
Subjects
Details
- ISSN :
- 00223859
- Database :
- OpenAIRE
- Journal :
- Journal of Postgraduate Medicine
- Accession number :
- edsair.doi...........6d977dd684616eba734f4c1260cd311a
- Full Text :
- https://doi.org/10.4103/jpgm.jpgm_1335_20